Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Patent: 9,371,377

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,371,377
Title:Anti-C5 antibodies having improved pharmacokinetics
Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
Inventor(s): Andrien, Jr.; Bruce A. (Guilford, CT), Sheridan; Douglas L. (Branford, CT), Tamburini; Paul P. (Kensington, CT)
Assignee: Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:14/923,879
Patent Claims:see list of patent claims

Details for Patent 9,371,377

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Alexion Pharmaceuticals, Inc. ULTOMIRIS ravulizumab-cwvz Injection 761108 2018-12-21 ⤷  Try it Free 2034-03-07
Alexion Pharmaceuticals, Inc. ULTOMIRIS ravulizumab-cwvz Injection 761108 2020-10-09 ⤷  Try it Free 2034-03-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.